11th Annual BioBusiness Forum

10:00 Chairperson's welcome and opening remarks Morning Session: Biotechnology Funding and Finance in a Challenging Capital Market Simon Haworth, MD, Team Ventures Inc. Morning Session: Biotechnology Funding and Finance in a Challenging Capital Market After a number of challenging years for the biotech community, 2010 saw a major growth in the amount of capital raised in biotech internationally. For the majority of early stage biotechs however, funding remains elusive with over 80% of money raised in 2010 going towards just 20% of the largest companies (compared with 0.4% towards the smallest 20% according to Ernst & Young) which is coupled with a sharply decreasing share of VC funding available as investors look towards other segments such as IT and media. These funding pressures are compounded by increased regulatory and payer scrutiny of new medicines, tranched payments typically tied to development goals, economic uncertainty and austerity measures worldwide. This BioBusiness focus day stream will delve into the underlying issues surrounding this current funding malaise and arm you with the key insight needed to ensure an attractive investment proposition for your company. Simon Haworth MD, Team Ventures Inc. Simon’s first career was in real estate, second career in team building and third career in fundraising.Simon established the Market Research function for international property agent Savills plc, where he gained his first IPO experience. He moved on to Arthur Andersen to develop his corporate finance skills and by then had already esta [read more]

10:10 Panel: Addressing biotech funding difficulties – How best to tackle this key challenge and where will the money come from to do so? Onno van de Stolpe, Chief Executive Officer, Galapagos David Phillips, Managing Partner, SR One Werner Lanthaler, Chief Executive Officer, Evotec Jorgen Thorball, Managing Partner, XOventure Life Science Experts For young biotechs, attracting seed and early stage funding has become increasingly difficult in recent years although anecdotal signs of recovery are beginning to emerge. High burn-rates of cash are typically seen in the sector, so given the huge capital requirements to deliver a product, this panel will address the strategies being employed by biotech CEOs and early stage investors to ensure an adequately funded R&D pipeline.   Big pharma – less willing to go into open ended licensing agreements Option deals, money dependant on success at each step forward Venture capital waiting longer for returns Biotechs – adapt to the new environment for survival Too many companies running too many projects lacking long term viability Rigour in selecting projects moving forward Limited capacity of smaller biotech portfolio management driving consolidation Venture capital – LPs with a smaller appetite for risk are pushing towards later stage, risk averse opportunities European VC trends The increasing requirement for proof before parting with money The solutions moving forward Alternative sources of funding for early stage ventures Large companies as investors Comparative advantages What mixture of funding options will be crucial to future success Chair: Jørgen Thorball Onno van de Stolpe Chief Executive Officer, Galapagos Onno van de Stolpe (CEO) founded Galapagos in 1999 and has grown the Company to its current level of about 800 employees. Galapagos is an integrated drug discovery company with a number of internal programs and two service divisions BioFocus and Argenta. For its internal programs, Galapagos has GSK, J&J, Roche and Servier as alliance partners. In these programs Gal [read more] David Phillips Managing Partner, SR One As Partner in SR One (GSK’s Corporate Venture Fund), David Phillips co-leads SR One in Europe’s investment activities as well as pioneering a new function to incubate and spin-out technologies from GSK. He brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellco [read more] Werner Lanthaler Chief Executive Officer, Evotec Dr Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product [read more] Jorgen Thorball Managing Partner, XOventure Life Science Experts Jørgen started his first companies in the early 80s before he was headhunted twice to corporate management positions in the pharmaceutical industry (Pharmacia and Aventis) from 1990 to 1997, being responsible for billion dollar product brands and the establishment and merger of companies. In this period he gained hands on experience in hospital, specialist, GP, [read more]

10:50 Panel: Is syndicating with corporate venture a smart strategy – Corporate venture as a value driver and potential saviour for biotech Deborah Harland, Partner (Vice President Business Investments), SR One Carole Nuechterlein, Head, Roche Venture Fund Melanie Lee, Chief Executive Officer, Syntaxin Andrew Sandham, Chairman and CEO, Kymab Once seen by traditional VCs as a potential limit to the partnering ability of a biotech to other Pharmas, in a reality characterised by tough access to capital Corporate Venture Capital (CVC) funding is now regarded as an important or even crucial source of capital, with 45% of European venture funding featuring CVC involvement in 2010. Are CVC funds consciously stepping into the breach to drive innovation, because other VCs are not investing or just opportunistic as VCs back out of early Life Science investment? The potential for CVC to add value to a small biotechs portfolio Reticence from start-ups to accepting this funding Multiple CVC investing trends Benefits to investors Competition to in-license resulting products Auction process and stakeholder experiences Bringing returns to your investors without sacrificing autonomy Biotech CEO perspectives of CVC What CVC funds are looking for and how to ensure you present a compelling business plan and strong value proposition to them Chair: Andrew Sandham Deborah Harland Partner (Vice President Business Investments), SR One Deborah joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 20 year tenure in the pharmaceutical industry. D [read more] Carole Nuechterlein Head, Roche Venture Fund Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel. Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A [read more] Melanie Lee Chief Executive Officer, Syntaxin Dr Melanie Lee Ph.D. CBE, FMedSci. D.Sc (Hons) Melanie’s academic grounding in molecular genetics in three complex systems of DNA repair and recombination, RNA splicing and cell cycle was a broad and an important foundation for her future career. Melanie was cited by Sir Paul Nurse in his inaugural ceremony in Stockholm on receipt of his Nobel Prize for Medicine [read more] Andrew Sandham Chairman and CEO, Kymab Andrew P Sandham, BSc DipM, Chairman & Chief Executive Officer, Kymab. Mr Sandham has 30 years experience in business development and marketing within the healthcare sector. He has played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pha [read more]

Morning refreshments and networkingSpeaker’s Corner 11:30 Morning refreshments and networking Morning refreshments and networking Morning refreshments and networking 11:30 Speaker’s Corner Speaker’s Corner During the break, visit an area of the event dedicated to interaction with the previous session’s speakers and panellists. This is your opportunity to network and speak openly about any questions not covered during their session.

12:00 Panel:Chasing alpha – Perspectives on the future of venture capital and how top players are crafting their top-line strategy for success Axel Polack, General Partner, TVM Capital Denise Pollard-Knight, CEO, Phase4 Ventures Francesco de Rubertis, Life Sciences Partner, Index Ventures Regina Hodits, General Partner, Wellington Partners Access to capital now is very different than it was five years ago, and it will be even more different five years from now as changes and challenges ripple through the industry. In response to the greater risk and uncertainty common in the biotech sector, VCs are having to change their investment strategies or risk being a victim of the ever increasing industry consolidation. 5 year predictions Will smaller or larger investments yield better returns? Do late investments show success while seed investments destroy portfolios? Promising regions and therapeutic areas Implications of consolidation and the current shakeout US investment interest in Europe – a developing trend? Creative ways providing quicker exit opportunities for investors Rolling up the sleeves and contributing to value creation For the biotech industry to thrive, is a favourable IPO environment necessary? Novel financing structures and the need to innovate Increasing the quality of investments and outcomes Developing closer relationships with Pharma How to capitalise on high-end academic partnerships How will the changes the pharma industry is currently experiencing affect conditions right now and in the future Chair: Axel Polack Axel Polack General Partner, TVM Capital Dr. Axel Polack joined TVM Capital in 2000, and is a General Partner for life sciences at TVM Capital GmbH, Munich, which manages Fund generations III to VI. He is a member of the Board of Directors of Noxxon Pharma AG (Berlin, Germany), Invendo Medical (Kissing, Germany, f-star (Vienna, Austria) and Probiodrug AG (Halle, Germany). Dr. Polack’s main scientific f [read more] Denise Pollard-Knight CEO, Phase4 Ventures Denise is the Managing Partner at Phase4 Ventures, a London-based venture capital firm that invests in Life Sciences in the US and Europe. She has over 14 years experience as a venture capitalist and was a Managing Director at Nomura prior to Phase4’s spin-out which was backed by Harbourvest. She is currently a Director of Albireo, Nabriva (Chaiman), Oncomed and [read more] Francesco de Rubertis Life Sciences Partner, Index Ventures Francesco de Rubertis is the General Partner of Index Ventures and is responsible for the firm's life sciences practice as well as Index's networks within the scientific community. His areas of expertise include biotechnology and biopharmaceuticals. He joined Index in 1998 and has served on the board of several companies including Addex, Genmab, Bioxell, ParAlle [read more] Regina Hodits General Partner, Wellington Partners Regina joined Wellington Partners in spring 2010 as a part-time advisor and stepped up to General Partner in January 2011. Since 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences. Her industry experience and her strong scientific background will help the Wellington Life Sciences team to [read more]

12:40 Streamlining an organisational-wide due diligence process William Brown, Regional Director - Life Sciences, DataSite, Merrill DataSite Capitalising on a robust Life Science data room to provide an invaluable tool-set throughout the business    Getting the most out of a virtual data room and what this means for you Real world case study for a multi use VDR Preparing a data room launch - best practices and the key strategic and operational takeaway messages William Brown Regional Director - Life Sciences, DataSite, Merrill DataSite Will Brown has been with Merrill DataSite since July 2007 and brings with him over 10 years of IT Technical and Management experience.Will, formally responsible for DataSite clients in the UK and in Italy, and more recently Quebec Canada, is now based in Paris from where he heads up DataSite's European Life Sciences division. During tim [read more]

Networking LuncheonSpeaker’s Corner 13:00 Networking Luncheon Networking Luncheon 13:00 Speaker’s Corner Speaker’s Corner During the break, visit an area of the event dedicated to interaction with the previous session’s speakers and panellists. This is your opportunity to network and speak openly about any questions not covered during their session.

14:00 Afternoon Session: Driving Value from Effective Alliance Management and the Emerging Markets Afternoon Session: Driving Value from Effective Alliance Management and the Emerging Markets Over half of today’s top 20 medicines were either co-developed, co-marketed or in-licensed highlighting the importance of managing such crucial relationships. Since 2003 we’ve seen a dramatic shift in the way that pharma approaches partnering – in the right direction. Board rooms now understand that the effective management of development and commercialisation alliances is a key driver to determine which companies will be leading the industry forward and those that are left to be acquired. Both pharma and biotech companies are increasingly establishing in-house alliance management teams whose sole responsibility is to oversee these cross-divisional relationships, with some reporting an increased success rate of up to 25% when implemented effectively. This BioBusiness focus day stream will present you with an assessment of the current and future requirements for effective alliance management and provide clear strategies to maximise the value of partnership whilst managing risk and maximising value.

14:10 Case study: Alliance management from the top – implementing an energized alliance management organisational capability Kimberly Brue, Senior Director, Alliance Management, Biogen Idec Utilising an individual alliance as a best-practices pilot to establish a model of success Sharing transversally across the organisation and establishing a toolkit of practices that work Harmonising the approach – creating internal knowledge-sharing networks and encouraging best practices Importance of engagement and support of upper management External positioning of these capabilities and the benefits Kimberly Brue Senior Director, Alliance Management, Biogen Idec Kimberly Brue joined Biogen Idec as Senior Director, Alliance Management, within Program Leadership and Management. In this role, she is responsible for the Tysabri collaboration, managing interactions with Elan including all joint governance committees. Additionally, she will be working within the organization in order to create a consistent alliance approach w [read more]

14:50 Panel: When alliances go bad – Facing the issues and developing solutions to rescue a failing relationship or managing the termination Nicholas Adams, Chief Business Officer, Clavis Pharma Dimitri Dimitriou, Chief Executive Officer, ImmuPharma Damian Marron, Chief Executive Officer, Trophos When an alliance is entered into, the interests of both parties overlap. Over the natural progression of the partnership there can be a divergence of this mutual interest and the overlap can cease to exist, often through no fault of either party. Given this potential outcome, a key question for those managing an alliance is how do you deal with this fact? This panel delves into why the challenge can’t be removed, but can be effectively mitigated and presents effective strategies you can employ to ensure an appropriate response and mutually beneficial outcome. Choosing a partner with a higher probability of alignment on the key deal points At the outset of the partnership – Contractual preparation for all potential outcomes Anticipating future scenarios and developing the provisions in the initial contract What are the variables affecting the structure of the alliance Responsibilities and obligations of each party Identifying and managing issues as they happen Monitoring the working relationship between the parties and picking up early the warning signals Communication and adjustments to the relationship Preparing for terminating the alliance After the breakup Opportunities and challenges for small companies Managing perceptions externally Reputation implications for the large companies Keeping investor confidence Potential funding implications Professional communications Chair: Dimitri Dimitriou Nicholas Adams Chief Business Officer, Clavis Pharma Nicholas Adams, Chief Business Officer at Clavis Pharma, has more than 23 years of experience in the healthcare industry. For the past 12 years, he worked for the UK-quoted cancer company Antisoma plc, the majority of which as Vice President Business Development and a member of the senior management team. During his time at Antisoma, he gained experience across [read more] Dimitri Dimitriou Chief Executive Officer, ImmuPharma Mr Dimitriou, has over 20 years’ experience in the pharmaceutical and biotech industry. His past roles include Senior Director, Worldwide Business Development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He is the founder and [read more] Damian Marron Chief Executive Officer, Trophos Damian Marron, a highly experienced executive with strong experience in orphan diseases, has been CEO of Trophos since June 2008.Under his tenure, Trophos has spearheaded major EU funded consortia of leading global experts and specialists working on orphan diseases including ALS. He has also pushed through a Phase III trial for ALS and attracted EUR 34 million in funding. This inc [read more]

15:30 Panel: Creating opportunities in established markets by harnessing innovation from emerging regions Carl Firth, Chief Executive Officer & Founder, ASLAN Pharmaceuticals George Yeh, President, Taiwan Liposome Company (TLC) Lee Eng Hin, Senior Fellow, Agency for Science, Technology and Research (A*STAR) With the competition for promising in-licensing opportunities at fever pitch, many are looking for late stage opportunities outside the normal high value areas and investigating emerging markets. This panel will look at emerging market strategies with respect to their approach for these regions, the kinds of issues being faced and how best to forge your own strategy. The importance of the emerging markets to overall strategy Establishing a local presence Effective regional approaches Knowing the regional capabilities Tapping into their interests Addressing the issue of scientific credibility Capitalising on healthcare stimulus and grants When to form collaborations vs. acquire Talent development solutions Nurturing and funding the innovation The regulatory aspects of the emerging markets Case studies and war stories detailing successful examples Carl Firth Chief Executive Officer & Founder, ASLAN Pharmaceuticals Dr Carl Firth is Founder and CEO of ASLAN Pharmaceuticals, an Asia enabled pharmaceutical company that develops novel medicines for global markets. Previously, he was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions. Prior t [read more] George Yeh President, Taiwan Liposome Company (TLC) George Yeh joined TLC in 2002 as President. He leads TLC’s operations, responsible for strategic planning, business development, product licensing, and management of corporate funding. In a relatively short period of time, he grew TLC into one of the fastest‐growing drug delivery companies in Asia. In 2006, TLC was named top 100 private companies by Red Herring [read more] Lee Eng Hin Senior Fellow, Agency for Science, Technology and Research (A*STAR) Dr Lee is currently a Senior Fellow with the Agency for Science, Technology and Research (A*STAR), Singapore. He is also a Professor in Orthopaedic Surgery at the National University of Singapore, Emeritus Consultant at the National University Hospital and Senior Consultant at the KK Women’s and Children’s Hospital. He was the former Executive Director of the Bi [read more]

BioBusiness networking drinks receptionSpeaker’s Corner 16:10 BioBusiness networking drinks reception BioBusiness networking drinks reception BioBusiness networking drinks reception 16:10 Speaker’s Corner Speaker’s Corner During the break, visit an area of the event dedicated to interaction with the previous session’s speakers and panellists. This is your opportunity to network and speak openly about any questions not covered during their session.